𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Treatment modalities in hematology: Imatinib mesylate as therapy for chronic myeloid leukemia

✍ Scribed by A. Gratwohl

Publisher
Carden Jennings Publishing
Year
2002
Tongue
English
Weight
212 KB
Volume
76
Category
Article
ISSN
0925-5710

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Acute myeloid leukemia developing during
Acute myeloid leukemia developing during imatinib mesylate therapy for chronic myeloid leukemia in the absence of new cytogenetic abnormalities
✍ Attaphol Pawarode; Sheila N.J. Sait; Alain Nganga; Lionel J. Coignet; Maurice Ba πŸ“‚ Article πŸ“… 2007 πŸ› Elsevier Science 🌐 English βš– 171 KB

The BCR/ABL tyrosine kinase inhibitor imatinib mesylate produces a high rate of cytogenetic responses in patients with Philadelphia (Ph)-positive chronic myeloid leukemia (CML), but secondary clonal chromosome abnormalities may develop in Ph-negative cells, and acute myeloid leukemia (AML) has been